Fernández-Deaza G, Caicedo-Martinez M, Serrano B, Roura E, Castillo JS, de Sanjose S, Bruni L, Murillo R

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 415-423
Archivo PDF: 392.51 Kb.

RESUMEN

Objetivo. Describir directrices vigentes en los programas de tamizaje de cáncer de cuello uterino en Latinoamérica. Material y métodos. Se buscaron recomendaciones oficiales en instituciones de gobierno de 19 países, tanto para la población general como para mujeres viviendo con VIH (MVIH). Se complementó la información mediante consulta de la OMS a los Ministerios de Salud. Resultados. Las recomendaciones varían ampliamente entre países respecto a población objeto, pruebas e intervalos de tamizaje. Dieciséis países tienen recomendaciones actualizadas; sin embargo, la citología continúa siendo prueba primaria en la mayoría. Once países introdujeron las pruebas de VPH y ocho tienen estrategias de ver y tratar. Todos los países, excepto Costa Rica, tienen recomendaciones específicas para MVIH. Conclusión. A pesar de recientes actualizaciones, pocos países tienen abordajes adecuadamente alineados con la estrategia de eliminación de la OMS. Las recomendaciones para MVIH requieren mejor integración con los programas de tamizaje.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence andMortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin.

2. 2021;71(3):209-49. https://doi.org/10.3322/caac.216602. World Health Organization. Draft: Global Strategy towards the eliminationof cervical cancer as a public health program. Geneva: WHO, 2020 [cited2020 Jun 8]. Available from: https://www.who.int/publications/m/item/draft-global-strategy-towards-eliminating-cervical-cancer-as-a-public-health-problem

3. Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al.Impact of HPV vaccination and cervical screening on cervical cancerelimination: a comparative modelling analysis in 78 low-income and lowermiddle-income countries. Lancet. 2020;395(10224):575-90. https://doi.org/10.1016/S0140-6736(20)30068-4

4. International Agency for Research on Cancer. Global Cancer Observatory.Lyon: International Agency for Research on Cancer, 2020 [cited 2021Jan 29]. Available from: https://gco.iarc.fr/

5. Almonte M, Murillo R, Sánchez GI, González P, Ferrera A, Picconi MA, etal. Multicentric study of cervical cancer screening with human papillomavirustesting and assessment of triage methods in Latin America: theESTAMPA screening study protocol. BMJ Open. 2020;10(5):e035796.https://doi.org/10.1136/bmjopen-2019-035796

6. Murillo R, Herrero R, Sierra MS, Forman D. Cervical cancer in Centraland South America: Burden of disease and status of disease control. CancerEpidemiol. 2016;44(1):S121-30. https://doi.org/10.1016/j.canep.2016.07.015

7. World Health Organization, Pan American Health Organization.Cancer country profiles. OMS, PAHO, 2020 [cited2022 Jan 12]. Available from: https://www3.paho.org/hq/index.php?option=com_docman&view=list&slug=4-cancer-country-profiles-2020&Itemid=270&lang=es

8. World Health Organization. Comprehensive Cervical Cancer Control. Aguide to essential practice. Geneva: WHO, 2014 [cited 2020 Sep 3]. Availablefrom: https://www.who.int/reproductivehealth/publications/cancers/cervical-cancer-guide/en/

9. de Sanjose S, Holme F. What is needed now for successful scale-up ofscreening? Papillomavirus Res. 2019;7:173-5. https://doi.org/10.1016/j.pvr.2019.04.011

10. Pan American Health Organization. Plan of action for cervicalcancer prevention and control 2018-2030. Washington DC: PAHO,2018 [cited 2020 Jun 8]. Available from: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=mandatesstrategies-3448&alias=47584-plan-cervical-cancer-2018-2030&Itemid=270&lang=en

11. Lynge E, Törnberg S, von Karsa L, Segnan N, van Delden JJM. Determinantsof successful implementation of population-based cancer screeningprogrammes. Eur J Cancer. 2012;48(5):743-8. https://doi.org/10.1016/j.ejca.2011.06.051

12. Murillo R. Social inequalities in cancer in Latin America. In: Vaccarella S,Lortet-Tieulent J, Saracci R, Conway DI, Straif K, Wild CP, editors. Reducingsocial inequalities in cancer: Evidence and priorities for research. Lyon: IARCScientific Publication, 2019:223-6 [cited 2020 Jun 8]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Reducing-Social-Inequalities-In-Cancer-Evidence-And-Priorities-For-Research-2019

13. Instituto Nacional de Câncer, Ministério da Saúde. Diretrizes Brasileiraspara o Rastreamento do Câncer do Colo do Útero. Rio de Janeiro:Inca, 2016 [cited 2020 Jun 8]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizesparaorastreamentodocancerdocolodoutero_2016_corrigido.pdf

14. Ministerio de Salud. Guías Clínicas AUGE, Cáncer Cérvico Uterino.Santiago: Minsal, 2015 [cited 2020 Jun 8]. Available from: https://www.minsal.cl/wp-content/uploads/2015/09/GPC-CaCU.pdf

15. Ministerio de Salud y Protección Social. Guía de Práctica Clínica parala detección y manejo de lesiones precancerosas de cuello uterino. Colombia:Ministerio de Salud y Protección Social, 2014 [cited 2022 Jan 12].Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-lesiones-precancerosas-cuello-uterino-padres.pdf

16. Secretaría de Salud. Programa de Acción Específico 2007-2012. Cáncercervicouterino. Mexico City: Secretaría de Salud, 2008 [cited 2020 Jun8]. Available from: http://www.cnegsr.salud.gob.mx/contenidos/descargas/CaCu/pae_cacu.pdf

17. Secretaría de Salud. Programa de acción específico, prevención ycontrol del cáncer de la mujer 2013-2018. Mexico City: Secretaría deSalud, 2014 [cited 2020 Jun 8]. Available from: https://www.gob.mx/cms/uploads/attachment/file/10046/PrevencionyControldelCancerdelaMujer_2013_2018.pdf

18. Ministerio de Salud, Coordinación Nacional de Salud Sexual y Reproductiva.Normas de prevención, detección y seguimiento de las lesionespreinvasoras del cuello uterino y guías de manejo. Panamá: Ministerio deSalud, 2017 [cited 2020 Jun 8]. Available from: http://www.minsa.gob.pa/sites/default/files/programas/normas_de_prevencion_cacu.pdf

19. Arrossi S, Thouyaret L, Paul L. Prevención del cáncer cervicouterino. Recomendacionespara el tamizaje, seguimiento y tratamiento de mujeres enel marco de programas de tamizaje basados en el test de VPH: actualización.Buenos Aires: Instituto Nacional del Cáncer Argentina, 2015 [cited 2020Jun 8]. Available from: https://bancos.salud.gob.ar/sites/default/files/2018-10/0000000017cnt-manual_recomendaciones_tamizaje_2015_baja.pdf

20. Secretaría de Salud. Protocolo para el tamizaje y tratamiento de lesionespremalignas para la prevención del cáncer cervicouterino. Honduras:Secretaría de Salud, 2015 [cited 2022 Jan 12]. Available from: https://extranet.who.int/ncdccs/Data/HND_D1_Protocolo%20C%C3%A1ncer%20C%C3%A9rvicouterino%20(30%20NOV).pdf

21. Ministerio de Salud Pública y Asistencia Social. Guía de atención integralpara la prevención, detección y tratamiento de lesiones precursorasdel cáncer cérvico uterino. Guatemala: Ministerio de Salud Pública yAsistencia Social, 2020 [cited 2021 Feb 17]. Available from: https://osarguatemala.org/guia-de-atencion-integral-para-la-prevencion-deteccion-ytratamiento-de-lesiones-precursoras-del-cancer-cervico-uterino/

22. Fernández-Deaza G, Caicedo-Martínez M, Serrano B, Roura E, Castillo JS,Silvia de S, et al. Appendix A and B. Figshare 2022. Available from: https://doi.org/10.6084/m9.figshare.20235681.v1

23. World Health Organization, International Agency for Research onCancer, Working Group on the Evaluation of Cancer Preventive Agents.Cervix cancer screening. IARC Handbooks of Cancer Prevention. Lyon:IARC Press, 2005 [cited 2020 Jun 8]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervix-Cancer-Screening-2005

24. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-HirschPP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancerscreening in the general population. Cochrane Database Syst Rev.2017;8(8):CD008587. https://doi.org/10.1002/14651858.CD008587.pub2

25. Chrysostomou A, Stylianou D, Constantinidou A, Kostrikis L. CervicalCancer Screening Programs in Europe: The Transition Towards HPV Vaccinationand Population-Based HPV Testing. Viruses. 2018;10(12):729. https://doi.org/10.3390/v10120729

26. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK,Barry MJ, Caughey AB, et al. Screening for Cervical Cancer: US PreventiveServices Task Force Recommendation Statement. JAMA. 2018;320(7):674-86. https://doi.org/10.1001/jama.2018.10897

27. Canadian Task Force on Preventive Health Care. Recommendationson screening for cervical cancer. CMAJ. 2013;185(1):35-45. https://doi.org/10.1503/cmaj.121505

28. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervicalprecancer and reaching underscreened women by using HPV testing onself samples: updated meta-analyses. BMJ. 2018;363:k4823. https://doi.org/10.1136/bmj.k4823

29. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P,Velasco-Mondragón E, et al. Self-collection of vaginal specimens for humanpapillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011;378(9806):1868-73.https://doi.org/10.1016/S0140-6736(11)61522-5

30. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, CuberliM, et al. Effect of self-collection of HPV DNA offered by communityhealth workers at home visits on uptake of screening for cervicalcancer (the EMA study): a population-based cluster-randomised trial.Lancet Glob Health. 2015;3(2):e85-94. https://doi.org/10.1016/S2214-109X(14)70354-7

31. Holme F, Jerónimo J, Maldonado F, Camel C, Sandoval M, Martínez-Granera B, et al. Introduction of HPV testing for cervical cancer screeningin Central America: The Scale-Up project. Prev Med. 2020;135:106076.https://doi.org/10.1016/j.ypmed.2020.106076

32. Frenk J, Gómez-Dantés O. Health Systems in Latin America: TheSearch for Universal Health Coverage. Arch Med Res. 2018;49(2):79-83.https://doi.org/10.1016/j.arcmed.2018.06.002

33. Joint United Nations Programme on HIV/AIDS. Seazing the Moment;tackling entrenched inequalities to end epidemics. Geneva: UNAIDS, 2020[cited 2020 Oct 5]. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf

34. Joint United Nations Programme on HIV/AIDS. HIV estimates withuncertainty bounds from 1990-present. Geneva: UNAIDS, 2021 [cited2022 Jan 12]. Available from: https://www.unaids.org/en/resources/documents/2021/HIV_estimates_with_uncertainty_bounds_1990-present

35. Mohammed D, Shukla P, Babayants Y, Sison R, Slim J. Increased proportionsof HIV-infected women met cervical cancer screening guideline in 2016. Int JWomens Health. 2018;10:83-7. https://doi.org/10.2147/IJWH.S153003

36. Abraham AG, D’Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, et al.Invasive cervical cancer risk among HIV-infected women: a North Americanmulticohort collaboration prospective study. Acquir Immune Defic Syndr.2013;62(4):405-13. https://doi.org/10.1097/QAI.0b013e31828177d7

37. World Health Organization. WHO guidelines for screening andtreatment of precancerous lesions for cervical cancer prevention. Geneva:WHO, 2013 [cited 2020 Oct 5]. Available from: https://apps.who.int/iris/bitstream/handle/10665/94830/9789241548694_eng.pdf